Abstract
Alzheimers disease (AD) is an age-related neurodegenerative disease that affects approximately 24 million people worldwide. A number of different risk factors have been implicated in AD, however, neuritic (amyloid) plaques are considered as one of the defining risk factors and pathological hallmarks of the disease. Complement proteins are integral components of amyloid plaques and cerebral vascular amyloid in Alzheimer brains. They can be found at the earliest stages of amyloid deposition and their activation coincides with the clinical expression of Alzheimers dementia. This review emphasizes on the dual key roles of complement system and complement regulators (CRegs) in disease pathology and progression. The particular focus of this review is on currently evolving strategies for design of complement inhibitors that might aid therapy by restoring the fine balance between activated components of complement system, thus improving the cognitive performance of patients. This review discusses these issues with a view to inspiring the development of new agents that could be useful for the treatment of AD.
Keywords: Alzheimer's disease, neurodegeneration, inflammation, β-amyloid peptide, complement, complement regulators, CD59, complement therapeutics
Current Neuropharmacology
Title: Implication of Complement System and its Regulators in Alzheimers Disease
Volume: 7 Issue: 1
Author(s): Martin V. Kolev, Marieta M. Ruseva, Claire L. Harris, B. Paul Morgan and Rossen M. Donev
Affiliation:
Keywords: Alzheimer's disease, neurodegeneration, inflammation, β-amyloid peptide, complement, complement regulators, CD59, complement therapeutics
Abstract: Alzheimers disease (AD) is an age-related neurodegenerative disease that affects approximately 24 million people worldwide. A number of different risk factors have been implicated in AD, however, neuritic (amyloid) plaques are considered as one of the defining risk factors and pathological hallmarks of the disease. Complement proteins are integral components of amyloid plaques and cerebral vascular amyloid in Alzheimer brains. They can be found at the earliest stages of amyloid deposition and their activation coincides with the clinical expression of Alzheimers dementia. This review emphasizes on the dual key roles of complement system and complement regulators (CRegs) in disease pathology and progression. The particular focus of this review is on currently evolving strategies for design of complement inhibitors that might aid therapy by restoring the fine balance between activated components of complement system, thus improving the cognitive performance of patients. This review discusses these issues with a view to inspiring the development of new agents that could be useful for the treatment of AD.
Export Options
About this article
Cite this article as:
Kolev V. Martin, Ruseva M. Marieta, Harris L. Claire, Morgan Paul B. and Donev M. Rossen, Implication of Complement System and its Regulators in Alzheimers Disease, Current Neuropharmacology 2009; 7 (1) . https://dx.doi.org/10.2174/157015909787602805
DOI https://dx.doi.org/10.2174/157015909787602805 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Translating Genetic Findings into Therapy in Parkinson Disease
Recent Patents on CNS Drug Discovery (Discontinued) Herbals and Natural Dietary Supplements in Psychiatric Practice
Recent Patents on CNS Drug Discovery (Discontinued) QSAR, Docking, and CoMFA Studies of GSK3 Inhibitors
Current Pharmaceutical Design Multiple Defects in Energy Metabolism in Alzheimers Disease
Current Drug Targets Correlation Analysis of Capillary APOE, VEGF and eNOS Expression in Alzheimer Brains
Current Alzheimer Research Soluble Forms of RAGE in Human Diseases: Clinical and Therapeutical Implications
Current Medicinal Chemistry The Glutathione System and its Regulation by Neurohormone Melatonin in the Central Nervous System
Central Nervous System Agents in Medicinal Chemistry Chitosan Nanoparticles: An Approbative System for the Delivery of Herbal Bioactives
The Natural Products Journal Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Cocaine Dependence and Stroke: Pathogenesis and Management
Current Neurovascular Research Colloidal Supramolecular Aggregates for Therapeutic Application in Neuromedicine
Current Medicinal Chemistry The Role of Vascular Factors in Late-Onset Sporadic Alzheimers Disease. Genetic and Molecular Aspects
Current Alzheimer Research Benefits of Resistance Training in Older Adults
Current Aging Science MRI of Central Nervous System (CNS) Vasculitis
Current Medical Imaging Selective Serotonin-norepinephrine Re-uptake Inhibition Limits Renovas-cular-hypertension Induced Cognitive Impairment, Endothelial Dysfunction, and Oxidative Stress Injury
Current Neurovascular Research Medicinal and Beneficial Health Applications of Tinospora cordifolia (Guduchi): A Miraculous Herb Countering Various Diseases/Disorders and its Immunomodulatory Effects
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cognitive Training in Patients with Alzheimer's Disease: Findings of a 12-month Randomized Controlled Trial
Current Alzheimer Research Modulation and Detection of Tau Aggregation with Small-Molecule Ligands
Current Alzheimer Research Stroke as a Consequence of Sleep Apnea: Epidemiology, Pathophysiology and Treatment Strategies
Current Respiratory Medicine Reviews Properties of Neurotoxic Peptides Related to the Bri Gene
Protein & Peptide Letters